(S)-2-(Boc-Amino)non-8-Enoic Acid CAS 300831-21-4 Tsarkake>98.0% (GC) ee> 99.0% Paritaprevir Intermediate Factory

Takaitaccen Bayani:

Suna: (S)-2-(Boc-Amino) ba-8-Enoic Acid

Saukewa: 300831-21-4

Tsafta:> 98.0% (GC)

ku:>99.0%

Bayyanar: Ruwan Brown

Matsakaici na Paritaprevir (CAS: 1216941-48-8)

E-Mail: alvin@ruifuchem.com

Aika mana imel

Cikakken Bayani

Samfura masu dangantaka

Tags samfurin

Bayani:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer and supplier of (S)-2-(Boc-Amino)non-8-Enoic Acid (CAS: 300831-21-4) with high quality, commercial production. Ruifu Chemical offers a wide range of chiral compounds. We can provide Certificate of Analysis (COA), worldwide delivery, small and bulk quantities available. Please contact: alvin@ruifuchem.com

Abubuwan Sinadarai:

Sunan Sinadari	(S)-2-(Boc-Amino) ba-8-Enoic Acid
Makamantu	(S)-2-(tert-Butoxycarbonylamino) ba-8-Enoic Acid;(S)-2-(Boc-Amino)-8-Acid Nonenoic;(2S)-2- [(2-Methylpropan-2-yl) oxycarbonylamino] ba-8-Enoic Acid;(2S)-2-{[(tert-butoxy) carbonyl]amino}non-8-Enoic Acid
Lambar CAS	300831-21-4
Lambar CAT	Saukewa: RF-CC347
Matsayin Hannun jari	A Stock
Tsarin kwayoyin halitta	Saukewa: C14H25NO4
Nauyin Kwayoyin Halitta	271.35
Yawan yawa	1.035± 0.06 g/cm3
Alamar	Ruifu Chemical

Ƙayyadaddun bayanai:

Abu	Ƙayyadaddun bayanai
Bayyanar	Ruwan Brown
Tsarkake / Hanyar Bincike	> 98.0% (GC)
ee	>99.0%
Matsayin Gwaji	Matsayin Kasuwanci
Amfani	Matsakaici na Paritaprevir (CAS: 1216941-48-8)

Kunshin & Ajiya:

Kunshin: Fluorinated Bottle, 25kg/Drum, ko bisa ga abokin ciniki ta bukata

Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi

Amfani:

FAQ:

Aikace-aikace:

(S) -2- (Boc-Amino) ba-8-Enoic Acid (CAS: 300831-21-4) ana iya amfani dashi azaman tsaka-tsaki a cikin kira na Paritaprevir (CAS: 1216941-48-8) da analogs masu alaƙa.Paritaprevir shine mai hanawa na NS3/4A na ƙarni na biyu, wani sashi ne na maganin haɗe-haɗe-haɗe-haɗe-haɗe-haɗe-haɗe-haɗe-haba-tsare, wanda ba shi da interferon wanda Enanta Pharmaceuticals da AbbVie suka haɓaka.An amince da tsayayyen kashi na Paritaprevir, Ombitasvir da Ritonavir da aka ɗauka tare da Dasabuvir don maganin cutar HCV genotype 1 na yau da kullun a cikin Amurka da EU a cikin 2014, kuma an ƙara yarda da maganin cututtukan HCV na genotype 4 na kullum ba tare da cirrhosis ta Amurka ba. FDA a cikin 2015.